Home
Scholarly Works
Atezolizumab plus bevacizumab versus lenvatinib as...
Conference

Atezolizumab plus bevacizumab versus lenvatinib as first-line systemic therapy for treatment of hepatocellular carcinoma in a real-world population: Outcomes from the HCC CHORD database.

Authors

Freeman M; Krishnan T; Lee CL; Dibajnia P; Ramjeesingh R; Vasconcelos JPS; Lyubetska H; Ding PQ; Lim HJ; Knox JJ

Volume

42

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Publication Date

June 1, 2024

Name of conference

Special Clinical Science Symposia

Conference place

ELECTR NETWORK

Conference start date

May 29, 2024

Conference end date

May 29, 2024

Conference proceedings

JOURNAL OF CLINICAL ONCOLOGY

Issue

16

ISSN

0732-183X

Labels

Fields of Research (FoR)

Contact the Experts team